DURECT (DRRX) Q4 2024 earnings summary

Executive summary

• Focused on developing larsucosterol for alcohol-associated hepatitis, achieving key milestones including Phase 2b AHFIRM trial publication and FDA breakthrough therapy designation, following the sale of the ALZET product line and streamlining operations.

• Completed sale of ALZET product line for $17.5 million, using proceeds to fully repay term loan and strengthen the balance sheet.

• The company is seeking approximately $20 million in funding to initiate a Phase 3 larsucosterol trial, with readiness to start upon securing capital.

Financial highlights

• 2024 revenues were $2 million, down from $2.6 million in 2023; Q4 2024 revenues were $500,000, down from $0.9 million year-over-year.

• Net income for Q4 2024 was $7.8 million, compared to a $1.4 million net loss in Q4 2023; FY 2024 net loss was $7.9 million, compared to $27.6 million in FY 2023.

• R&D expenses dropped to $10.4 million in 2024 from $29.4 million in 2023, and to $1.9 million in Q4 2024 from $5.6 million in Q4 2023, mainly due to lower clinical trial costs.

• SG&A expenses decreased to $10 million in 2024 from $12.7 million in 2023, and to $2 million in Q4 2024 from $2.2 million in Q4 2023.

• Cash and investments at year-end 2024 were $12 million, compared to $29.8 million at the end of 2023.

Outlook and guidance

• Cash on hand is expected to fund operations through Q3 2025.

• Plans to initiate Phase 3 larsucosterol trial in 2025, with topline results expected within two years of trial start, pending sufficient funding.

• Actively exploring business development and financing options to support continued larsucosterol development.